---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-011487"
form_type: "8-K"
ticker: "HRTX"
cik: "0000818033"
company_name: "HERON THERAPEUTICS, INC. /DE/"
filed_at: "2023-04-03T23:59:59+00:00"
generated_at: "2026-06-17T07:26:45.962669+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Heron Therapeutics appoints Craig Collard as CEO, Adam Morgan as Chairman

## Summary
- Craig Collard appointed CEO effective April 3, 2023, succeeding Barry Quart who stepped down.
- Adam Morgan elected Chairman of the Board; CEO and Chairman roles are now separate.
- Collard's compensation: $650,000 base salary, 75% target bonus, equity grants including 3M stock options and up to 4.25M performance-based options.
- Board reduced to seven members as part of governance changes.
- Departure of Barry Quart not due to any disagreement; he may assist with transition under a consulting agreement.

## SEC filing metadata
- accession: 0000950170-23-011487
- form_type: 8-K
- ticker: HRTX
- cik: 0000818033
- company_name: HERON THERAPEUTICS, INC. /DE/
- filed_at: 2023-04-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818033/000095017023011487/0000950170-23-011487-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818033/000095017023011487/hrtx-20230330.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-011487
- JSON: https://secwatch.observer/filing/0000950170-23-011487.json
- Plain text: https://secwatch.observer/filing/0000950170-23-011487.txt

## Key facts
- Executive change
  Craig Collard was appointed as Chief Executive Officer at HERON THERAPEUTICS, INC. /DE/.
  - Action: appointed
  - Role: Chief Executive Officer
  source text: appointed Craig Collard as the Company’s Chief Executive Officer, effective April 3, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/818033/000095017023011487/0000950170-23-011487-index.htm
- Executive change
  Barry Quart departed as Chief Executive Officer at HERON THERAPEUTICS, INC. /DE/.
  - Action: ceased
  - Role: Chief Executive Officer
  source text: Mr. Collard succeeds Barry Quart, who will cease to serve as the Company’s Chairman, Chief Executive Officer and a director as of the Effective Date
  evidence_url: https://www.sec.gov/Archives/edgar/data/818033/000095017023011487/0000950170-23-011487-index.htm
- Executive change
  Adam Morgan was appointed as Chairman of the Board at HERON THERAPEUTICS, INC. /DE/.
  - Action: appointed
  - Role: Chairman of the Board
  source text: appointed current director Adam Morgan to serve as Chairman of the Board, effective as of the Effective Date
  evidence_url: https://www.sec.gov/Archives/edgar/data/818033/000095017023011487/0000950170-23-011487-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.